JPRN-UMIN000031960招募中未知
A clinical study of WT1 peptide-based cancer vaccine WT1 Trio for myeloproliferative neoplasms - WT1 Trio cancer vaccine for MP
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •- >=10% of blasts in the peripheral blood - active infectious disease including tuberculosis. - active autoimmune disease and/or collagen disease -severe complications (grade >=3 according to CTCAE v4.0) - severe mental disorders - participation in other clinical trial which could affect the results of the study - having other malignant disease within three years prior to the registration -Dicided as inadequate by the principal investigator or a subinvestigator
研究者
相似试验
已完成
1 期
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000002001Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35
尚未招募
1 期
Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant gliomaMalignant Glioma DIPGJPRN-UMIN000013258Osaka university graduate school of medicine18
已完成
1 期
Phase I clinical trial of Wilms tumor 1 peptide vaccination for patients with advanced canceradvanced cancerJPRN-UMIN000002771Tokyo Women's Medical University18
尚未招募
2 期
WT1 peptide-based cancer vaccine in patients with high risk rhabdomyosarcoma, a multicenter, phase 2 clinical studyrhabdomyosarcomaJPRN-UMIN000013325Osaka university graduate school of medicine Pediatrics33